A Flexible Regimen of Combination Antihypertensive Therapy for Lower Blood Pressure to the Lower Target Level. Viewpoint of Cardiologist and Clinical Pharmacologist
https://doi.org/10.20996/1819-6446-2019-15-2-265-270
Abstract
Modern tactics of antihypertensive therapy with fixed dose combination or with free combinations of antihypertensive drugs are reviewed in the article. The evidence that a flexible regimen of combination antihypertensive therapy is more reasonable in the modern treatment of arterial hypertension is presented. The question of the characteristics of hypertensive patients in whom lowering blood pressure to lower target levels may be useful to improve the prognosis is discussed considering the results of the analysis of data on participants in a randomized clinical trial SPRINT. Approaches to reducing the incidence of adverse events caused by antihypertensive therapy in such patients in general and in elderly and senile patients who have not only a higher likelihood of achieving advantages of more intensive antihypertensive therapy regimens for influencing the prognosis, but also a higher risk of complications, due to therapy are considered. The problem of less high efficacy of using replicated antihypertensive drugs (generics) compared to the original drugs is discussed.
Supporting agencies: Pfizer
About the Authors
S. R. Gilyarevskiy
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Sergey R. Gilyarevskiy - MD, PhD, Professor, Chair of Clinical Pharmacology and Therapy.
Barrikadnaya ul. 2/1, Moscow, 1 25993
M. V. Golshmid
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Maria V Golshmid - MD, PhD, Associate Professor, Chair of Clinical Pharmacology and Therapy.
Barrikadnaya ul. 2/1, Moscow, 1 25993
G. Yu. Zaharova
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Galina Yu. Zaharova - MD, PhD, Associate Professor, Chair of Clinical Pharmacology and Therapy.
Barrikadnaya ul. 2/1, Moscow, 1 25993
I. M. Kuzmina
Sklifosovsky Research Institute of Emergency Medicine
Russian Federation
Russian Federation
Irina M. Kuzmina - MD, PhD, Head of Department of Emergency Cardiology.
Bolshaya Sukharevskaya pl. 3, Moscow, 129090
I. I. Sinitsina
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Irina I. Sinitsina - MD, PhD, Professor, Chair of Clinical Pharmacology and Therapy.
Barrikadnaya ul. 2/1, Moscow, 1 25993
References
1. Simpkin A.L., Schwartzstein R.M. Tolerating Uncertainty - Tie Next Medical Revolution? N Engl J Med. 2016;37:1713-15. doi:10.1056/NEJMpl606402.
2. Whelton P.K., Carey R.M., Aronow W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71 :e13-e115. doi: 10.1161/HYP,0000000000000065.
3. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-104. doi:10.1093/eurheartj/ehy339.
4. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:21 03-16. doi:10.1056/NEJMoa1511939.
5. Phillips R.A., Xu J., Peterson L.E., et al. Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension. J Am Coll Cardiol. 2018;71:1601-10. doi:10.1016/j.jacc.2018.01.074.
6. Williamson J.D., Supiano M.A., Applegate W.B., et al.; SPRINT research group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >75 years: a randomized clinical trial. JAMA. 2016;31 5:2673-82. doi:10.1001/jama.2016.7050.
7. Liang Y, Vetrano D.L., Qiu C. The role of biological age in the management of hypertension in old age: Does SPRINT tell the whole story? Int J Cardiol. 2016;222:699-700. doi:10.1016/j.ij-card.2016.08.085.
8. Post Hospers G., Smulders YM., Maier A.B., et al. Relation between blood pressure and mortality risk in an older population: role of chronological and biological age. J Intern Med. 2015;277:488-97. doi:10.1111/joim.12284.
9. Muller M., Smulders YM., de Leeuw P.W., Stehouwer C.D. Treatment of hypertension in the oldest old: a critical role for frailty? Hypertension. 2014;63:433-41. doi:10.1161/HYPERTENSION-AHA.113.00911.
10. Windham B.G., Griswold M.E., Lirette S., et al. Effects of Age and Functional Status on the Relationship of Systolic Blood Pressure with Mortality in Mid and Late Life: The ARIC Study J Gerontol A Biol Sci Med Sci. 2017;72:89-94. doi:10.1093/gerona/glv162.
11. Odden M.C., Moran A.E., Coxson P.G., et al. Gait Speed as a Guide for Blood Pressure Targets in Older Adults: A Modeling Study J Am Geriatr Soc. 2016;64:101 5-23. doi: 10.1111/jgs.14084.
12. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. A Randomized Clinical Trial. JAMA. 2019;321(6): 553-561. doi:10.1001/jama.2018.21442.
13. Egan B.M., Bandyopadhyay D., Shaftman S.R., et al. Initial monotherapy and combination therapy and hypertension control the first year Hypertension. 2012;59:1 124-31. doi:10.1161/HYPER-TENSIONAHA.112.194167.
14. Mancia G., Zambon A., Soranna D., et al. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J Hypertens. 2014;32:1708-1 5. doi:10.1097/HJH.0000000000000222.
15. Corrao G., Parodi A., Zambon A., et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28:1 58490. doi:10.1097/HJH.0b013e328339f9fa.
16. Mancia G., Rea F, Cuspidi C., et al. Blood pressure control in hypertension. Pros and cons of available treatment strategies. J Hypertens. 2017;35:225-33. doi:10.1097/HJH.0000000000001181.
17. Mu L., Mukamal K.J. Treatment intensification for hypertension in US ambulatory medical care. J Am Heart Assoc. 2016;5:e004188. doi:10.1161/JAHA.116.004188.
18. Okonofua E.C., Simpson K.N., Jesri A., et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47:345-51. doi:10.1161/01.HYP.0000200702.76436.4b.
19. Rea F, Corrao G., Merlino L., Mancia G. Initial Antihypertensive Treatment Strategies and Therapeutic Inertia. Hypertension. 2018;72:846-53. doi:10.1161/HYPERTENSIONAHA.118.11308.
20. Mallat S.G., Tanios B.Y, Itani H.S., et al. Free versus Fixed Combination Antihypertensive Therapy for Essential Arterial Hypertension: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11 (8):e01 61 285. doi:10.1371/journal.pone.0161285.
21. Gupta A.K., Arshad S., Poulter N.R. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399-407. doi:10.1161/HY-PERTENSIONAHA.109.139816.
22. European Medicines Agency Committee for Medicinal Products for Human Use (2017) Guideline on Clinical Development of Fixed Combination Medicinal Products. London, UK: EMA; 2017.
23. Aronson J.K. Medication errors resulting from the confusion of drug names. Expert Opin Drug Saf. 2004;3:167-72. doi:10.1517/eods.3.3.167.31069.
24. Bramley D.E. The ability of anaesthetists to identify generic medications from trade names. Anaesth Intensive Care. 2009;37:624-9. doi:10.1177/0310057X0903700401.
25. Schwab M., Oetzel C., Morike K., et al. Using Trade Names. Arch Intern Med. 2002;1 62:1 065.
26. Bobb A., Gleason K., Husch M., et al. The Epidemiology of Prescribing Errors. Arch Intern Med. 2004;164:785. doi:10.1001/archinte.162.9.1065.
27. Karnon J., McIntosh A., Dean J., et al. Modelling the expected net benefits of interventions to reduce the burden of medication errors. J Health Serv Res Policy. 2008;13:85-91. doi:10.1258/jhsrp.2007.007011.
28. Moriarty F, Bennett K., Fahey T Fixed-dose combination antihypertensives and risk of medication errors. Heart. 2019;105(3):204-9. doi:10.1136/heartjnl-2018-313492.
29. Angeli F, Reboldi G., Mazzotta G., et al. Fixed-dose combination therapy in hypertension: cons. High Blood Press Cardiovasc Prev. 2012;19:51-4. doi:10.2165/11632070-000000000-00000.
30. Bramlage P., Schmidt S., Sims H. Fixed-dose vs free-dose combinations for the management of hy-pertension-An analysis of 81 958 patients. J Clin Hypertens (Greenwich). 2018;20:705-15. doi:10.1111/jch.13240.
31. Materson B.J. Enhancing dosage flexibility in combination therapy. J Clin Hypertens (Greenwich). 2007;9:796-9. doi:10.1111/j.1751-7176.2007.tb00007.x.
32. Sadia M., Isreb A., Abbadi I., et al. From 'fixed dose combinations' to 'a dynamic dose combiner': 3D printed bi-layer antihypertensive tablets. Eur J Pharm Sci. 2018;123:484-94. doi :10.1016/j.ejps.2018.07.045.
33. Bubnova M. G., Kuznetsova I. V., Aronov D. M., et al. Study of the clinical efficacy of two drugs of amlodipine (original and reproduced) in patients with arterial hypertension and obesity: a randomized, crossover study. Cardiovascular Therapy and Prevention. 2016;15:17-27 (In Russ.) doi:10.15829/1728-8800-2016-5-17-27.
Review
For citations:
Gilyarevskiy S.R., Golshmid M.V., Zaharova G.Yu., Kuzmina I.M., Sinitsina I.I. A Flexible Regimen of Combination Antihypertensive Therapy for Lower Blood Pressure to the Lower Target Level. Viewpoint of Cardiologist and Clinical Pharmacologist. Rational Pharmacotherapy in Cardiology. 2019;15(2):265-270. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-2-265-270
Views:
870
Email this article 